Swedish Orphan Biovitrum AB (publ) : Sobi publishes Report for the First Quarter 2013

   Swedish Orphan Biovitrum AB (publ) : Sobi publishes Report for the First
                                 Quarter 2013

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
first quarter 2013. Revenues for the quarter totalled MSEK 528.5 (506.7), with
continued momentum across the commercial portfolio and several significant
advances in the pipeline.

Business Highlights

  *Received FDA approval of Kineret® for the treatment of NOMID.
  *Presented new phase 3 Haemophilia data, reinforcing long-lasting
    protection from bleeding for patients.
  *Received EMA approval to manufacture Kineret drug substance with partner
    Boehringer Ingelheim.
  *Entered into three key partnerships which further strengthen the partner
    network across the portfolio.

Financial Highlights

  *Total revenues increased by 4 percent to MSEK 528.5 (506.7). Adjusted for
    one-time items in the prior year, revenues increased 12 percent.
  *Gross margin increased to 57 percent (51) driven by efficiency gains in
    production and completion of technology transfer for Kineret.
  *Ended the quarter with a cash position of MSEK 401.2.
  *Outlook for 2013 remains unchanged.

"The quarter demonstrated continued commercial momentum, with 4 percent growth
year over year and expansion of our Key Therapeutic Areas of Inflammation and
Genetics in existing and new markets," said Geoffrey McDonough, CEO and
President. "In addition, our pipeline posted several significant events
including the FDA approval of Kineret for the treatment of NOMID and the
release of additional data from the phase 3 trials of our long-lasting
recombinant clotting factors for Haemophilia."


Sobi's report for the first quarter 2013 can be found on

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late-stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi
is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of
SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is
listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com

For more information please contact

Media relations       Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications        Relations
T: +46 70410 71 80   T: +46 8 697 20 00
oskar.bosson@sobi.com jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 26 April 2013 at 8:00 CET

Sobi Report for the First Quarter 2013


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.